Abstract:BackgroundThe combination of primary aldosteronism (PA) and alterations in plasma renin activity (PRA) is a leading cause of secondary hypertension. An accurate measurement of Renin Angiotensin-Aldosterone System (RAAS) pathway improves the recognition of symptoms related to stroke, coronary disease, heart failure and metabolic syndrome.MethodsPreviously, surrogate matrices have been used when demonstrating the analytical performance of LC-MS/MS clinical research methods for the measurement of aldosterone and angiotensin I. Here, we have developed an analytically sensitive and reliable analytical strategy for simultaneous measurement of Aldosterone and Angiotensin I in human matrices. In-house calibrators and quality control samples were prepared, containing varying ranges of both aldosterone (20-2000pg/mL; 55-5548pmol/L) and angiotensin 1 (0.6-240ng/mL; 0.46-185nmol/L). The samples were extracted using the OasisTM MAX 96-well μElution plate and then separated through the ACQUITYTM UPLCTM I-Class FL System using a XBridgeTM Premier Peptide BEHTM C18 Column, over a run time of 3 minutes. Samples were then injected to XevoTM TQ Absolute Mass Spectrometer, using both positive and negative acquisition modes. The downstream LC-MS/MS data analysis was performed using MassLynxTM MS Software. The analytical performance was demonstrated by extracting and quantifying two replicates of samples on two occasions per day over five separate days. Additionally, the stability of aldosterone and angiotensin I over the period of incubation (3-5hr) was evaluated, which is necessary when investigating the plasma renin activity in human Serum/Plasma samples.ResultsHigh reproducibility and repeatability were both determined, indicating total precision and repeatability (<15%CV) for both analytes and no significant changes were found in Aldosterone and Angiotensin I concentrations over 3-5hr of incubation. No significant system carryover ( 0.992 for all analyses at different incubation times. The analytical sensitivity of the clinical research method allows for precise quantification at 55 pmol/L for aldosterone and 0.46 nmol/L/hr for angiotensin I, with both analytes providing S/N (PtP) ≥10:1 and %RSD of <15% at these concentrations.ConclusionsAn analytically sensitive and selective clinical research method has been developed for the analysis of aldosterone and angiotensin I, using the Xevo TQ Absolute Mass Spectrometer. The Xevo TQ Absolute Mass Spectrometer enables the simultaneous analysis of physiologically low levels of aldosterone and plasma renin activity in human samples, (20pg/mL; 55pmol/L), (0.6ng/mL; 0.46nmol/h/L). A single test that improves instrument utilization, reduces cost, and allows the user to expand their existing test menu on the same platform has been established.

A Comprehensive Profiling of Renin-Angiotensin System in Mouse and Human Plasma by a Rapid Quantitative Analysis of 14 Angiotensin Peptides Using Ultrahigh-Performance Liquid Chromatography with Tandem Mass Spectrometry.

Robust analysis of angiotensin peptides in human plasma: Column switching-parallel LC/ESI-SRM/MS without adsorption or enzymatic decomposition

Analysis of Peptides in Plasma by High Performance Liquid Chromatography Coupled with Electrospray Ionization Mass Spectrometry

Development and validation of an LC-MS/MS method for the simultaneous quantitation of angiotensin (1-7), (1-8), (1-9) and (1-10) in human plasma

Simultaneous Determination Of Notoginsenoside R1, Ginsenoside Rg(1), Re, Rb-1 And Icariin In Rat Plasma By Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry

A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay for simultaneous quantification of aldosterone, renin activity, and angiotensin II in human plasma

A-067 Simultaneous Measurement of Aldosterone and Plasma Renin Activity in Human Serum Using Liquid Chromatography Coupled to Tandem Mass Spectrometry for Clinical Research

Peptide and Protein Quantification Using Automated Immuno-MALDI (iMALDI)

Newly developed radioimmunoassay for Human Angiotensin-(1-12) measurements in plasma and urine

Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney

Quick and High-Throughput Quantification of Β-Agonists Residues in Animal-Derived Foods Using Enzymatic Probe Sonication Coupled with Automatic Solid-Phase Extraction

Comprehensive Profiling of Amino Acids and Derivatives in Biological Samples: A Robust UHPLC-MS/MS Method for Investigating Acute Lung Injury

A biomarker panel of secondary hypertension is simultaneously quantified by coupling of magnetic solid‐phase extraction and liquid chromatography–tandem mass spectrometry

Development of a rapid and robust hydrop interaction liquid chromatography tandem mass spectrometry method for the detection of 13 endogenous amino acids as well as trimethylamine oxide in serum and tissues of the mice

Development, validation and application of a UHPLC-MS/MS method for quantification of the adiponectin-derived active peptide ADP355 in rat plasma

A Rapid Assay for Angiotensin-Converting Enzyme Activity Using Ultra-Performance Liquid Chromatography-Mass Spectrometry

Quantification of peptides using N-terminal isotope coding and C-terminal derivatization for sensitive analysis by micro liquid chromatography-tandem mass spectrometry.

Development and application of sequential window acquisition of all theoretical mass spectra data acquisition modes on ultra‐high‐performance liquid chromatography triple‐quadrupole/time‐of‐flight mass spectrometry for metabolic profiling of amino acids in human plasma

Blood to Biomarker Quantitation in Under One Hour with Rapid Proteomics using a Hyperthermoacidic Protease

Rapid Quantification of Lisinopril in Human Plasma by Liquid Chromatography/tandem Mass Spectrometry

Elucidating important factors and corresponding method optimization for sensitive detection of small peptide drugs in human urine by solid‐phase extraction and UPLC‐HRMS: The influence of MS scan modes, protein precipitants, and ammonium formate